Drug Profile
Research programme: fibroblast growth factor-2 binding peptides - sigma-tau
Latest Information Update: 29 Sep 2010
Price :
$50
*
At a glance
- Originator sigma-tau SpA
- Class Peptides
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 08 Jan 2008 Preclinical trials in Immunological disorders in Italy (unspecified route)